Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | NPC1 | O15118 | 6/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | MAOB | P27338 | 6/20 | 0.57 |
| ▸ | MAOA | P21397 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238020 | 0.93 | RAB9A (0.80) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL1724568 | 0.91 | MAPT (0.85) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL10338453 | 0.85 | KDM4E (0.80) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL2069145 | 0.85 | RAB9A (0.80) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL10441792 | 0.84 | MAPT (0.74) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL12289030 | 0.84 | RAB9A (0.78) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL4434901 | 0.84 | RAB9A (0.78) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL13640741 | 0.84 | KDM4E (0.62) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL2070406 | 0.84 | NPC1 (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E | |
| SCHEMBL12892699 | 0.81 | ALDH2 (0.78) | ALDH1A1MAPTSMN1; SMN2NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-05-19 | — | — | US | disclosed |
| US-9198895-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150240275-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-08-27 | — | — | US | disclosed |
| US-8993296-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8957109-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140315264-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8669088-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20130150568-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-8461361-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8399232-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8163795-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20100330627-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALDH1A1 3444/4885MAPT 2679/4885SMN1; SMN2 3697/4885 |
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALDH1A1 3444/4885MAPT 2679/4885SMN1; SMN2 3697/4885 |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALDH1A1 3444/4885MAPT 2679/4885SMN1; SMN2 3697/4885 |
| US-20100330627-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | DHODH, DHPS, HPGD | ALDH1A1 374/4885MAPT 3932/4885SMN1; SMN2 4816/4885 |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALDH1A1 3354/4885MAPT 1677/4885SMN1; SMN2 3767/4885 |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALDH1A1 3444/4885MAPT 2679/4885SMN1; SMN2 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.